|Articles|October 28, 2019

Shikha Garg, MD, MPH: Influenza Vaccination Associated With Reduced Odds of Severe Outcomes

A study by Shikha Garg, MD, MPH, and her team with the US Centers for Disease Control and Prevention boosts the evidence base for the benefit of influenza vaccination.

Segment Description: Shikha Garg, MD, MPH, medical officer in the Influenza Division at the US Centers for Disease Control and Prevention, presented a study at IDWeek 2019 examining whether influenza vaccination reduces the risk of severe outcomes among hospitalized adults with influenza A(H1N1)pdm09.

Interview transcript: (modified slightly for readability):

Contagion®: Can you speak a little bit about the impetus for this study?

Garg: So what we wanted to do was, we really wanted to increase the evidence base for the benefits of influenza vaccination. Every year, millions of people get influenza, hundreds of thousands of people get hospitalized with influenza, and tens of thousands of people die from influenza.

So what we really wanted to do was show the benefits of vaccination in preventing some of these severe outcomes.

Contagion®: Could you summarize the findings?

Garg: We used the Influenza Hospitalizations Surveillance Network, or FluServ-NET, to look at data from over 40,000 adults who were hospitalized with influenza over 5 seasons, across over 250 acute care hospitals, in 13 states. And what we did was look at severe outcomes in these people including death, ICU admission, mechanical ventilation, and pneumonia in adults who had received the flu vaccine versus those who hadn't received the flu vaccine prior to their hospitalization.

So what we found was that in adults 18-64 years of age, influenza vaccine reduced the odds of death by 36%, mechanical ventilation by 34%, ICU admission by 19%, and pneumonia . by 17%.

And then in adults 65 years older, flu vaccine was associated in those with A(H1N1) with reduced odds of mechanical ventilation by almost one half, and ICU admission by almost a third. And in that group, it also shortened the hospital length of stay.

So overall, we saw that flu vaccination, although it's not always perfect—it's variable in how it works, and that some people who get vaccinated can still get sick—flu vaccine really did reduce the risk of severe outcomes.

Contagion®: What are you hoping clinicians to take away from this research?

Garg: I hope that they can take away the messaging that there's a lot of different benefits of flu vaccine. So again, I think, flu vaccine effectiveness can vary from year to year. But I think this study really shows that even if people get sick, despite getting vaccinated, that they can really have some substantial benefits of flu vaccine.

So it's really important to vaccinate all people 6 months and older every year. And I'll also add that all of the 3 different flu viruses—A(H1N1), A(H3N2), and B—circulate every year. And so, the study shows that you get protection against the influenza A(H1N1) virus, but all viruses circulate every year.

Contagion®: Is there anything else you'd like to add?

Garg: It's flu season now, and it's really important for everyone to get vaccinated—and preferably by the end of October.

The study, Influenza Vaccination Reduces Risk of Severe Outcomes among Adults Hospitalized with Influenza A(H1N1)pdm09, FluSurv-NET, 2013-2018, was presented Thursday, October 3, 2019, at IDWeek 2019 in Washington, DC.


Related to this article

Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.